The complexity of myotonic DM1 pathogenesis driven by toxic r(CUG)exp in DMPK mRNA has spurred efforts to develop multitarget small molecules with distinct mechanisms of action operating simultaneously. The gene discussed is DMPK; the disease is myotonic dystrophy type 1.